233 related articles for article (PubMed ID: 17180514)
1. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Yoshioka T; Sakayori M; Kato S; Chiba N; Miyazaki S; Nemoto K; Shibata H; Shimodaira H; Ohtsuka K; Kakudo Y; Sakata Y; Ishioka C
Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
3. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
[TBL] [Abstract][Full Text] [Related]
8. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
Miyazaki A; Kobayashi J; Yamamoto T; Kido Y; Takemura K; Abe M; Tomihara K; Dehari H; Nakamori K; Nagai I; Hiratsuka H
Oral Oncol; 2008 May; 44(5):471-6. PubMed ID: 17826308
[TBL] [Abstract][Full Text] [Related]
9. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
[TBL] [Abstract][Full Text] [Related]
10. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K
Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
16. Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma.
Satomura H; Nakajima M; Sasaki K; Yamaguchi S; Domeki Y; Takahashi M; Muroi H; Kubo T; Kikuchi M; Otomo H; Ihara K; Kato H
Int Surg; 2015 Jun; 100(6):1153-8. PubMed ID: 26414837
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
